000021893 001__ 21893
000021893 005__ 20180210144204.0
000021893 0247_ $$2pmid$$apmid:19499989
000021893 0247_ $$2DOI$$a10.1007/s12268-012-0207-7
000021893 037__ $$aPreJuSER-21893
000021893 041__ $$aeng
000021893 082__ $$a570
000021893 1001_ $$0P:(DE-HGF)0$$aHeck, A.$$b0
000021893 245__ $$aExpressionsoptimierung in Mikroorganismen
000021893 260__ $$aHeidelberg$$bSpektrum$$c2012
000021893 300__ $$a449 - 451
000021893 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article
000021893 3367_ $$2DataCite$$aOutput Types/Journal article
000021893 3367_ $$00$$2EndNote$$aJournal Article
000021893 3367_ $$2BibTeX$$aARTICLE
000021893 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000021893 3367_ $$2DRIVER$$aarticle
000021893 440_0 $$06961$$aBiospektrum$$v18$$x0947-0867$$y4
000021893 500__ $$aRecord converted from VDB: 12.11.2012
000021893 520__ $$aVitamin D receptor (VDR) expression has been shown to be upregulated in several tumors and is supposed to represent an important endogenous response to tumor progression. To investigate the role of the VDR gene and its influence on 25(OH)D(3) and 1,25(OH)(2)D(3) plasma levels in thyroid carcinoma, we analyzed four VDR polymorphisms in patients and healthy controls (HC).Patients with thyroid carcinoma (n = 172) (n = 132 for papillary and n = 40 for follicular) and HC (n = 321) were genotyped for the ApaI (rs7975232), TaqI (rs731236), BsmI (rs1544410), and FokI (rs10735810) polymorphisms within the VDR gene and correlated with 25(OH)D(3) and 1,25(OH)(2)D(3) plasma levels.The genotypes AA of the ApaI (rs7975232) and FF of the FokI (rs10735810) polymorphisms were significantly less frequent (12.5% vs. 35.2% and 25% vs. 42.1%, respectively, both corrected p [p(c)] = 0.04) in patients with follicular thyroid cancer (FTC) than in HC. Additionally, the haplotypes, Ta (57.5% vs. 41.4%; p(c) = 0.0207), af (24.6% vs. 14.3%; p(c) = 0.0116), Tab (51.1% vs. 36.8%; p(c) = 0.0495), and Tabf (18.7% vs. 13.6%; p(c) = 0.0240) were more frequent, whereas the haplotypes AF (17.1% vs. 37.2%; p(c) = 0.0008), BF (11.4% vs. 31.9%; p(c) = 0.012), tF (7.9% vs. 25.5%; p(c) = 0.0016), and tABF (7.6% vs. 23%; p(c) = 0.0115) were less frequent in the FTC patients compared to HC. Neither genotype nor haplotype frequencies differed between patients with papillary thyroid cancer (PTC) and HC. Further, individuals with PTC and FTC had a significantly lower level of circulating 1,25(OH)(2)D(3) compared to controls. In contrast, no differences of the 25(OH)D(3) concentration between patients and HC were observed. VDR polymorphisms were not associated with 25(OH)D(3) and 1,25(OH)(2)D(3) plasma levels.Lower circulating levels of 1,25(OH)(2)D(3) are observed in patients with differentiated thyroid carcinoma. Further, while the alleles AA and FF of the ApaI (rs7975232) and FokI (rs10735810) VDR polymorphisms and the haplotype tABF confer to protection from follicular carcinoma, the haplotype Tabf appeared to be associated with an increased FTC risk. Since this is the first report associating VDR polymorphisms with thyroid carcinoma, these findings need to be confirmed in studies with larger numbers of patients.
000021893 536__ $$0G:(DE-Juel1)FUEK410$$2G:(DE-HGF)$$aBiotechnologie$$cPBT$$x0
000021893 588__ $$aDataset connected to Pubmed
000021893 650_2 $$2MeSH$$aAutoantibodies: immunology
000021893 650_2 $$2MeSH$$aCalcifediol: metabolism
000021893 650_2 $$2MeSH$$aCalcitriol: metabolism
000021893 650_2 $$2MeSH$$aCarcinoma, Papillary, Follicular: genetics
000021893 650_2 $$2MeSH$$aCarcinoma, Papillary, Follicular: pathology
000021893 650_2 $$2MeSH$$aCell Differentiation
000021893 650_2 $$2MeSH$$aFemale
000021893 650_2 $$2MeSH$$aGenotype
000021893 650_2 $$2MeSH$$aHaplotypes
000021893 650_2 $$2MeSH$$aHumans
000021893 650_2 $$2MeSH$$aMale
000021893 650_2 $$2MeSH$$aNeutrophil Infiltration
000021893 650_2 $$2MeSH$$aPolymorphism, Genetic: genetics
000021893 650_2 $$2MeSH$$aReceptors, Calcitriol: genetics
000021893 650_2 $$2MeSH$$aThyroid Gland: immunology
000021893 650_2 $$2MeSH$$aThyroid Neoplasms: genetics
000021893 650_2 $$2MeSH$$aThyroid Neoplasms: pathology
000021893 650_2 $$2MeSH$$aVitamin D: physiology
000021893 650_7 $$00$$2NLM Chemicals$$aAutoantibodies
000021893 650_7 $$00$$2NLM Chemicals$$aReceptors, Calcitriol
000021893 650_7 $$01406-16-2$$2NLM Chemicals$$aVitamin D
000021893 650_7 $$019356-17-3$$2NLM Chemicals$$aCalcifediol
000021893 650_7 $$032222-06-3$$2NLM Chemicals$$aCalcitriol
000021893 7001_ $$0P:(DE-HGF)0$$aTielker, D.$$b1
000021893 7001_ $$0P:(DE-HGF)0$$aErnst, J.F.$$b2
000021893 7001_ $$0P:(DE-HGF)0$$aFreudl, R.$$b3
000021893 7001_ $$0P:(DE-HGF)0$$aBott, M.$$b4
000021893 7001_ $$0P:(DE-Juel1)129053$$aOldiges, M.$$b5$$uFZJ
000021893 7001_ $$0P:(DE-Juel1)129076$$aWiechert, W.$$b6$$uFZJ
000021893 7001_ $$0P:(DE-HGF)0$$aPietruszka, J.$$b7
000021893 7001_ $$0P:(DE-HGF)0$$aWilhelm, S.$$b8
000021893 7001_ $$0P:(DE-HGF)0$$aRosenau, F.$$b9
000021893 7001_ $$0P:(DE-HGF)0$$aDrepper, T.$$b10
000021893 7001_ $$0P:(DE-HGF)0$$aJaeger, K.-E.$$b11
000021893 773__ $$0PERI:(DE-600)2203536-9$$a10.1007/s12268-012-0207-7$$gVol. 18, p. 449 - 451$$p449 - 451$$q18<449 - 451$$tBiospektrum$$v18$$x0947-0867$$y2012
000021893 8567_ $$uhttp://dx.doi.org/10.1007/s12268-012-0207-7
000021893 909CO $$ooai:juser.fz-juelich.de:21893$$pVDB
000021893 9131_ $$0G:(DE-Juel1)FUEK410$$1G:(DE-HGF)POF2-890$$2G:(DE-HGF)POF2-800$$baußerhalb PoF$$kPBT$$lohne FE$$vBiotechnologie$$x0
000021893 9132_ $$0G:(DE-HGF)POF3-581$$1G:(DE-HGF)POF3-580$$2G:(DE-HGF)POF3-500$$aDE-HGF$$bKey Technologies$$lKey Technologies for the Bioeconomy$$vBiotechnology$$x0
000021893 9141_ $$y2012
000021893 915__ $$0StatID:(DE-HGF)0020$$2StatID$$aNo Peer Review
000021893 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000021893 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000021893 9201_ $$0I:(DE-Juel1)VDB56$$gIBT$$kIBT-2$$lBiotechnologie 2$$x0$$zab 31.10.10 weitergeführt IBG-1
000021893 970__ $$aVDB:(DE-Juel1)138049
000021893 980__ $$aVDB
000021893 980__ $$aConvertedRecord
000021893 980__ $$ajournal
000021893 980__ $$aI:(DE-Juel1)IBG-1-20101118
000021893 980__ $$aUNRESTRICTED
000021893 981__ $$aI:(DE-Juel1)IBG-1-20101118